The Impact of Dupilumab on Work Productivity and Emotional Health in CRSwNP: A Multicentric Study in Northeast Italy

Chronic rhinosinusitis with nasal polyps (CRSwNP) in the severe forms is associated with a poor quality of life. Dupilumab has been suggested as an add-on treatment option for severe CRSwNP. Severe CRSwNP patients treated with Dupilumab in different rhinological units were considered for this study...

Full description

Saved in:
Bibliographic Details
Published in:Journal of personalized medicine 2024-05, Vol.14 (5), p.468
Main Authors: Ottaviano, Giancarlo, Roccuzzo, Giuseppe, Lora, Lucia, Bison, Elisabetta, Tosin, Enrico, Calvanese, Leonardo, Cestaro, Walter, Locatello, Luca Giovanni, Corlianò, Fabrizio, Stellin, Marco, Baldovin, Maria, Trimarchi, Maria Vittoria, Bertocco, Anna Giulia, Maculan, Marco, Scarpa, Bruno, Saccardo, Tommaso, Nicolai, Piero
Format: Article
Language:English
Subjects:
Asthma
Disease
Emotions
Endoscopy
Hospitals
Inflammation
Mental health
Otolaryngology
Polyps
Quality of life
Rhinosinusitis
Sinuses
Steroids
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic rhinosinusitis with nasal polyps (CRSwNP) in the severe forms is associated with a poor quality of life. Dupilumab has been suggested as an add-on treatment option for severe CRSwNP. Severe CRSwNP patients treated with Dupilumab in different rhinological units were considered for this study via their evaluation at the baseline at first and the consequential follow-up at 6-, 12-, and 24 months from the first administration. At baseline (T0) and at each follow-up, patients underwent NPS, Sinonasal Outcome Test (SNOT)-22, Visual Analogue Scale (VAS) for smell, and Sniffin' sticks identification test (SSIT). The SNOT-22 domains for function and emotion were also analysed separately. Two hundred and seventeen patients with at least 6 months of follow-up were included. All parameters have improved during treatment ( < 0.0001). Noticeably, both the function and emotion SNOT-22 domains have improved within 6 months of treatment and have continued to progress during every interval within 12 months from the baseline, positively influencing patients' emotivity and augmenting their social and economic performances. Dupilumab improves the QoL of CRSwNP patients with good effects on the reported productivity and emotional health. Clinicians should pay attention to these two aspects when dealing with patients affected by severe CRSwNP.
ISSN:2075-4426
2075-4426
DOI:10.3390/jpm14050468